University of Oxford
Collegiate research university in Oxford, England, and a leading source of vaccines and spinouts.
On 24 July 2026 the Oxford Vaccine Group dosed the first volunteer in the world's first Bundibugyo Ebola vaccine trial, testing a ChAdOx1 shot made by the Serum Institute of India with $8.6m from CEPI.
Last refreshed: 4 October 2026 · Appears in 2 active topics
How many deep-tech spinouts has the University of Oxford produced?
Timeline for University of Oxford
Mentioned in: CEPI awards Minapharm US$16.5m for Ebola
Pandemics and BiosecurityMentioned in: Oxford puts EU gas at 67% on 1 November
European Energy MarketsMentioned in: Moa raises £22.2m to outrun resistance
UK Startups and InnovationEbola trial doses its first patient
Pandemics and BiosecurityEPSRC doubles AI-lab spend to £60m
UK Startups and InnovationBackground
The University of Oxford is a collegiate research university in Oxford, England, with teaching dating to at least the 12th century. Professor Irene Tracey has been its vice-chancellor since January 2023. Oxford University Innovation turns its research into companies.
Its medical scientists sit inside the Bundibugyo Ebola response beyond vaccines. Oxford co-runs WHO's randomised treatment trial with DR Congo's INRB and the Institute of Tropical Medicine in Antwerp, testing remdesivir, MBP134 and obeldesivir; it enrolled its first patient in Ituri on 2 July 2026.
The university's reach runs well past medicine. Oxford physicists worked with Imperial College on the AION atom-interferometer result published in Nature on 17 June 2026, the step before building the full-scale AION-10 detector planned for Oxford's Beecroft building. In June 2026 the engineering research council EPSRC placed one of two new AI laboratories at Oxford, building AI that runs on cheap chips. Its Reuters Institute for the Study of Journalism publishes the annual Digital News Report.
Oxford's vaccine reached volunteers first
When the Bundibugyo Ebola emergency began in May 2026, no vaccine existed for the species. On 1 June CEPI split $62m across three platforms, and Oxford's share was $8.6m for a ChAdOx1 candidate manufactured at the Serum Institute of India. Funders then expected no human trial for at least 12 months.
Oxford beat that estimate. The Oxford Vaccine Group dosed its first volunteer on 24 July, the first Bundibugyo vaccine trial anywhere. By 27 August, when CEPI funded Egypt's Minapharm to start a rival candidate, Oxford's shot was already in Phase 1 alongside Moderna's mRNA version in Canada.
Oxford spinouts draw large rounds
Oxford's laboratories feed companies that raised some of Britain's larger 2026 rounds. Quantum Motion, spun out of UCL and Oxford, closed a $160m Series C on 7 May 2026. The British Business Bank put in £40m, its largest direct cheque since its £6.6bn mandate began in April. The Firm builds quantum processors on standard silicon chip processes.
On 23 July Moa Technology, another Oxford spinout, raised £22.2m to develop herbicides that work in new ways, after screening more than 900,000 compounds. Neither product has yet proved itself commercially: Quantum Motion's machine sits at the National Quantum Computing Centre, and Moa's chemistry is untested in a real field.